Keyphrases
Brain Metastases
100%
Phase I Trial
100%
Temozolomide
100%
Protracted Course
100%
Vinorelbine
100%
Maximum Tolerated Dose
33%
Chemotherapy
16%
Non-small Cell Lung Cancer (NSCLC)
16%
Lung Cancer
16%
Phase I Study
16%
Thrombocytopenia
16%
Median Survival
16%
Phase II Trial
16%
Primary Tumor
16%
Breast
16%
In(III)
16%
Lipophilic
16%
Escalating Dose
16%
Neutropenia
16%
Radiological Response
16%
Lymphopenia
16%
Dose-limiting Toxicity
16%
Starting Dose
16%
New Regimen
16%
Spectrum Agent
16%
Pharmacology, Toxicology and Pharmaceutical Science
Phase I Trials
100%
Temozolomide
100%
Vinorelbine
100%
Brain Metastasis
100%
Maximum Tolerated Dose
33%
Phase II Trials
16%
Chemotherapy
16%
Lung Cancer
16%
Lymphocytopenia
16%
Small Cell Lung Cancer
16%
Thrombocytopenia
16%
Primary Tumor
16%
Neutropenia
16%
Diseases
16%